4.4 Osteoporosis Screening, Prevention & Therapeutic Sequencing

4.4 Osteoporosis Screening, Prevention & Therapeutic Sequencing

BCACP Exam Anchor: Ambulatory bone health management requires mastery of dual-energy X-ray absorptiometry (DXA) diagnostic criteria, FRAX risk thresholds, precise oral bisphosphonate administration protocols, bisphosphonate holiday criteria, denosumab cessation rebound risks, and sequential therapeutic algorithms for anabolic agents (teriparatide, abaloparatide, romosozumab).

1. Diagnostic Criteria & Risk Stratification (DXA & FRAX)

According to the Bone Health & Osteoporosis Foundation (BHOF) and AACE/ACE guidelines, screening DXA is recommended for all women age $\ge 65$, all men age $\ge 70$, and postmenopausal women or men age 50–69 with clinical risk factors (e.g., glucocorticoid use $\ge 5\text{ mg/day}$ prednisone equivalent for $\ge 3\text{ months}$, rheumatoid arthritis, parental hip fracture, alcohol $\ge 3\text{ drinks/day}$, smoking).

DXA T-Score & Clinical Diagnostic Thresholds

• T-Score Definition: The number of standard deviations (SD) by which the patient's Bone Mineral Density (BMD) differs from the mean BMD of a healthy young adult reference population.
  • Normal: $\text{T-score} \ge -1.0$
  • Osteopenia (Low Bone Mass): $\text{T-score between } -1.0\text{ and } -2.5$
  • Osteoporosis: $\text{T-score} \le -2.5$ at the lumbar spine, femoral neck, total hip, or 33% (1/3) radius.
• Clinical Diagnosis Criteria (Any ONE establishes Osteoporosis):
  1. DXA T-score $\le -2.5$ at lumbar spine, femoral neck, or total hip.
  2. Occurrence of a low-trauma fragility fracture (fall from standing height or less) of the hip or spine, regardless of BMD T-score.
  3. Osteopenia (T-score $-1.0\text{ to } -2.5$) plus a low-trauma fragility fracture of the humerus, pelvis, or distal forearm.
  4. Osteopenia (T-score $-1.0\text{ to } -2.5$) plus an elevated FRAX 10-year fracture probability exceeding intervention thresholds.

FRAX (Fracture Risk Assessment Tool) Intervention Cutoffs

In treatment-naive patients with osteopenia, pharmacotherapy is indicated if the 10-year calculated probability is:

• Major Osteoporotic Fracture (Clinical Spine, Forearm, Hip, Shoulder): $\mathbf{\ge 20\%}$
• Hip Fracture Probability: $\mathbf{\ge 3.0\%}$

2. Foundational Calcium & Vitamin D Therapy

All pharmacologic therapies require adequate baseline calcium and vitamin D repletion to ensure efficacy and avoid severe hypocalcemia.

3. Bisphosphonate Pharmacotherapy & Drug Holidays

Bisphosphonates are synthetic pyrophosphate analogues that bind avidly to hydroxyapatite crystals in bone, inhibiting the enzyme farnesyl pyrophosphate synthase in osteoclasts to induce osteoclast apoptosis and suppress bone resorption.

Agent Comparison & Fracture Efficacy

Oral Bisphosphonate Administration Rules

To maximize negligible oral bioavailability (<1%) and prevent severe chemical esophagitis and esophageal ulceration:

1. Take immediately upon waking in the morning with 6 to 8 ounces of plain water only (no coffee, juice, tea, or mineral water).
2. Take at least 30 minutes before the first food, beverage, or any other oral medication (60 minutes for oral ibandronate).
3. Remain completely upright (sitting or standing) for at least 30 minutes (60 minutes for ibandronate); do not lie down until after the first meal.

Adverse Effects & Safety Precautions

• Renal Cutoff: Avoid/contraindicated if $\text{CrCl} < 30–35\text{ mL/min}$ or in acute renal failure.
• Hypocalcemia: Pre-existing hypocalcemia must be corrected before administration.
• Atypical Femur Fractures (AFF): Subtrochanteric or diaphyseal femoral stress fractures associated with prolonged antiresorptive suppression. Patients often present with prodromal dull, aching thigh or groin pain.
• Osteonecrosis of the Jaw (ONJ): Exposed necrotic bone in the maxillofacial region. Risk heightened following invasive dental procedures (extractions, implants). Perform routine dental exam before initiation.

Bisphosphonate Drug Holiday Protocol

Because bisphosphonates accumulate in bone matrix and provide sustained antiresorptive efficacy after cessation, a temporary drug holiday is considered:

• Low-to-Moderate Fracture Risk: Re-evaluate after 5 years of oral bisphosphonates (or 3 years of IV zoledronic acid). If T-score is $>-2.5$ and no new fractures have occurred, initiate a drug holiday for 2 to 3 years, monitoring BMD and bone turnover markers every 1–2 years.
• High Fracture Risk (T-score $\le -2.5$ at hip, or prior fragility fracture): Continue therapy for up to 10 years of oral therapy (or 6 years of IV zoledronic acid), or consider switching to an anabolic agent.

4. Denosumab (RANKL Inhibitor) & Rebound Fracture Phenomenon

• Mechanism: Fully human monoclonal antibody that binds Receptor Activator of Nuclear Factor-κB Ligand (RANKL), blocking its interaction with RANK receptors on osteoclasts and suppressing osteoclast maturation, function, and survival.
• Dosing: 60 mg Subcutaneously once every 6 months administered by a healthcare professional.
• Renal Safety & Hypocalcemia Risk: Denosumab is not eliminated by the kidneys and requires no dose adjustment in CKD stages 1 to 5. However, patients with advanced CKD (eGFR <30 mL/min or dialysis) have an exceptionally high risk of severe, life-threatening hypocalcemia due to baseline mineral and bone disorder. Confirm normal serum calcium and 25(OH)D prior to each injection.
• CRITICAL CLINICAL PEARL — Rebound Vertebral Fractures on Cessation:
  • Unlike bisphosphonates, denosumab does not incorporate into bone mineral. When denosumab is delayed or discontinued, bone turnover markers surge rapidly above baseline within 6 to 12 months, resulting in rapid bone loss and a high risk of multiple rebound vertebral fractures.
  • Mandatory Rule: Denosumab should never be stopped without immediately transitioning to an alternative antiresorptive agent (e.g., administering a single infusion of IV zoledronic acid 6 months after the final denosumab dose, or initiating oral alendronate for 1–2 years).

5. Anabolic Agents & Therapeutic Sequencing

Anabolic (bone-forming) agents are indicated for very high fracture risk (e.g., DXA T-score $\le -3.0$, prior fragility fracture within 12 months, multiple vertebral fractures, or fracture while on antiresorptive therapy).

Therapeutic Sequencing Principles: Anabolic-to-Antiresorptive

                                        Very High Fracture Risk
                      (T-score ≤ -3.0, Recent Fracture <12m, Multiple Fractures)
                                                   │
                                                   ▼
                                   STEP 1: Initiate Anabolic Therapy
                           • Teriparatide 20 mcg SubQ daily × 24 months OR
                           • Abaloparatide 80 mcg SubQ daily × 24 months OR
                           • Romosozumab 210 mg SubQ monthly × 12 months (if no CV risk)
                                                   │
                                                   ▼
                                  STEP 2: Consolidate with Antiresorptive
                                (Mandatory: Preserves Newly Formed Bone Mineral)
                           • Transition immediately to Oral Alendronate / Risedronate OR
                           • Transition to IV Zoledronic Acid 5 mg yearly OR
                           • Transition to Denosumab 60 mg SubQ q6m

• Why Sequence Anabolic First? Initiating an anabolic agent in treatment-naive bone produces massive, rapid increases in bone mineral density. If an antiresorptive is given first, it blunts the subsequent osteoblastic response to PTH analogues.
• Locking In BMD Gains: Newly formed trabecular bone is lost rapidly upon completing 12–24 months of anabolic therapy. Pharmacists must ensure an antiresorptive agent is initiated immediately upon completing anabolic therapy to consolidate and preserve structural gains.